Design and Evaluation of Losartan Transdermal Patch by Using Solid Microneedles as A Physical Permeation Enhancer

Document Type : Research article

Authors

1 Laboratorio 12: Sistemas Transdérmicos, Unidad de Investigación Multidisciplinaria, Departamento de Ingeniería y Tecnología, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Cuautitlán Izcalli, Estado de México, México.

2 Laboratorio 9: Toxicología, Unidad de Investigación Multidisciplinaria, Departamento de Ingeniería y Tecnología, Facultad de Estudios Superiores Cuautitlán. Universidad Nacional Autónoma de México, Cuautitlán Izcalli, Estado de México, México.

Abstract

The development of a losartan potassium patch for the treatment of hypertension established that a combination of hydrophobic and hydrophilic polymers, using as a plasticizer citroflex and succinic acid as a cohesion promoter result in homogeneous films. The effect of the Eudragit® E100, PVP K30, citroflex and succinic acid in the bioadhesion, postwetting bioadhesion, resistance to rupture and drug release, was studied. The succinic acid in synergy with the plasticizer (citroflex) modifies the characteristics of the polymeric matrix of Eudragit® E100, increasing the release and the resistance to rupture of transdermal patches. For the case of the hydrophilic polymer PVP K30, it increases the bioadhesion and drug release by creating porous matrices. From a previous experimental design, the optimal formulation was acquired, this formulation was characterized physicochemically. A transdermal patch was obtained with the next dimensions and characteristics: 28.46 ± 0.055 mm in diameter and 0.430 ± 0.008 mm in thickness, a bioadhesion of 1063.05 ± 60.33 gf, postwetting bioadhesion 995.9 ± 72.53 gf significantly decreased. The breaking strength was of 1301.5 ± 96.5 gf, surface pH patch of 6, constriction of 0% at 7 days, and 94.0366 ± 1.8617% of losartan content. The 93% of the drug is released at 4 h (n = 6), adjusting to the kinetic model of Higuchi and Peppas. In the in-vitro penetration studies by passive diffusion, a flow (J) of 42.2 μg/cm2h, a permeability constant (kp) of 2.1793E-03 cm/h and a latency time (tL) of 17.20 h and with the use of microneedles a flow (J) of 61.7 μg/cm2h, a permeability constant (kp) of 3.1869E-03 cm/h and a latency time (tL) of 17.74 h were obtained.

Graphical Abstract

Design and Evaluation of Losartan Transdermal Patch by Using Solid Microneedles as A Physical Permeation Enhancer

Keywords

Main Subjects



(1) OMS. Preguntas y respuestas sobre la hipertensión.[serial online] 2017 Dec [cited 2019 Dec], Availablefrom: URL: http://www.who.int/features/qa/82/es/.
(2) Fernández B, Molina Cuevas V and Cavazos MilanésB. Hipertensión Arterial. Guía para pacientes. Secretaría de Salud. México (2011) 5-41.(3) Harvey R. Farmacología. 6aed. Lippincott Williams and Wilkins. Barcelona (2016) 247-56.
(4) Bank D. Losartan. [serial online] 2017 Dec [cited2019 Dec], Available from: URL: https://www.drugbank.ca/drugs/DB00678.
(5) Betés de Toro M, Duran Hortolá M, Mestres MirallesC and Nogués Llort MR. Farmacología para fisioterapeutas. Médica Panamericana, Madrid (2008)250-300.
(6) Donnelly RF and Raj Singh TR. Novel delivery systems for transdermal and intradermal drug delivery.John Wiley and Sons, US (2015) 125-41.
(7) Allevato MA. Sistemas Terapéuticos Transdérmicos.Act. Terap. Dermatol. (2007) 30: 154-65.
(8) Llovet i Traveset E. CedimCat. Sistemas Transdérmicos. [serial online] 2017 Dec [cited 2017Dec], Available from: URL: http://cedimcat.info/index.php?option=com_contentview=article&id=23&Itemid=454&lang=es.
(9) Montero Hernández A and Gutiérrez Urbón J. La piel, también vehículo de administración de medicamentos. Farmacia (2013) 4: 72-5.
(10) Miyahira Yatacoa C, Herrero Ballestara J andLizán Tudelab L. Indicaciones de los parchestransdérmicos de los derivados opioides.Formación Médica Continuada en AtenciónPrimaria (2011) 18: 37-42.
(11) National Center for Biotechnology Information.PubChem Compound Database. [cited 2019 Dec19], (Accessed Dec 5, 2019). Available from:URL: CID=1110, https://pubchem.ncbi.nlm.nih.gov/compound/1110.
(12) U.S. Department of Health and Human Services,Food and Drug Administration, Center for Devices and Radiological Health. Regulatory Considerations for Microneedling Devices. [serial online]2018 March [cited 2017], Available: https://www.151 Almazan E et al. / IJPR (2020), 19 (1): 138-152fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm575923.pdf.
(13) U.S. Department of Health and Human Services,Food and Drug Administration, Center for Devicesand Radiological Health, Plastic and ReconstructiveSurgery, Devices Branch Division of General andRestorative, Devices Office of Device Evaluation.Guidance for Dermabrasion Devices. [serialonline] 2018 March [cited 2018 Mar 14], Availablefrom: URL: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073789.pdf.
(14) Serrano Castañeda P, Escobar Chavez JJ, RodriguezCruz IM, Melgoza LM and Martinez HernandezJ. Microneedles as enhancer of drug absorptionthrough the skin and applications in medicine and cosmetology. J. Pharm. Pharm. Sci. (2018) 21: 73-93.
(15) Serrano Castañeda P, Escobar Chávez JJ, MoralesHipólito A, Domínguez Delgado CL and AbregoReyes V. Microagujas y Transcutol® comopromotores de la penetración transdérmica desibutramina formulada en parche transdérmico.Rev. Cubana Farm. (2013) 47: 289-9.
(16) Serrano Castañeda P. Desarrollo y caracterizaciónde un parche transdérmico de pravastatinaacoplado a microagujas como promotor físico dela penetración transdérmica. [MSc dissertation].México, UAM Xochimilco (2014) 20-60.
(17) Ujjawal N and Devendra S. Formulation andCharacterization of Transdermal Patches of Losartan.Indian J. Pharm. Biol. Res. (2013) 1: 44-54.
(18) Serrano Castañeda P, Guadarrama Escobar OR,Escobar Chávez JJ, Melgoza Contreras LM, LópezArellano R and Revilla Vázquez AL. Liberaciónde pravastatina sódica formulada en matricespoliméricas a base de Quitosan/Pluronic F - 127.Rev. Cubana Farm. (2015) 49: 18-28.
(19) Dash S, Murthy P, Nath L and Chowdhury P.Kinetic modeling on drug release from controlleddrug delivery systems. Acta Pol. Hist. (2010) 67:
217-23.
(20) Escobar-Chávez JJ, Merino V, Díez Sales O, Ganem Quintanar A, Herráez M and Merino Sanjuán M.Transdermal nortriptyline hydrocloride patchformulated within a chitosan matrix intended to beused for smoking cessation. Pharm. Dev. Technol.(2011) 16: 162-9.
(21) Escobar-Chávez JJ. Estudio de la penetración através de la piel de naproxeno sódico utilizandoagentes promotores de penetración (azona ytranscutol), y de dicluconato de clorhexidinamediante iontoforesis [PhD dissertation]. México,FESC UNAM (2006) 3-37.
(22) Nirmal Shah, Ashvin Patel, Ghanshyam Patel,Jaymin Patel and Ankur Javia Seth. Designand development of losartan potassium loadedtransdermal drug delivery system. Pharma Sci.Monit. (2013) 4: 52-67.
(23) Walters K and Brain K. (eds.) Topical andtransdermal delivery. Pharmaceutical preformulation and formulation. A practical guide
from candidate drug selection to commercial dosage form. Informa Healthcare, US (2009) 475-527.
(24) Wu P, Tsai P, Lin S and Huang Y. Formulationoptimization of arecoline patches. Sci. World J. (2014) 2014: 1-7.
(25) Holowka E and Bathia S. (eds.) Drug delivery: materials design and clinical perspective. Springer Science, New York (2014) 7-116.
(26) Snejdrova E and Dittrich M. (eds.) Pharmaceutical applications of plasticized polymers. InTech,Czech Republic (2012) 69-90.
(27) Tapia B. Desarrollo de un Manual para el análisis de diseños experimentales aplicados a estudios de preformulación y formulación de medicamentos.[Bachelor dissertatio]. Estado de México, FESC UNAM (2013) 19-33.
(28) Aguiñaga A. Liberación Ionforética de Losartán formulado en un parche Transdérmico. [Master dissertation]. CDMX UAM Xochimilco (2014)10-40.
(29) Gennaro A and Remington JP. (eds.) Remington Farmacia. 20ª ed. Panamericana, Buenos Aires (2003) 970-1079.
(30) Garza Villegas J. Aplicación de diseño de experimentos para el análisis de secado de un producto. Universidad Autónoma de Nuevo León (2007) 10: 145-58.
(31) Sáez V, Hernáez E and Angulo S. Mecanismos de liberación de fármacos desde materiales polímeros. Iberoamericana de Polímeros (2004) 5: 55-70.
(32) Islam S, Khan R, Khatun M, Chowdhury A and Reza S. Studies on bio-adhesion of matrix tablets:II. Comparison on bio-adhesion strength and
 release profiles of theophylline anhydrous and itssodium glycinate salt. Dhaka Univ. J. Pharm. Sci. (2011) 10: 1-7.
(33) ACQUA. Analizadora de humedad Radwag PMC 50. [serial online] 2017 Dec [cited 2015
Sep], Available from: URL: http://linealab.net/analizadoras-de-humedad/33-analizadora-dehumedad-radwag-pmc.html.
(34) Dawson BG and Trapp R. (eds.) Bioestadística médica. Manual moderno, México (2005) 151-69.
(35) Escalona Rayo CF, Serrano Castañeda P, López  152
Losartan Transdermal Patch by Using MicroneedlesCervantes M and Escobar Chávez JJ. Optimization of unidirectional mucoadhesive buccal patches based on chitosan and pluronic® f-127 for metoprolol controlled release: in-vitro and ex-vivo evaluations. J. Pharm. Innov. (2019) 2019: 1-13.
(36) Secretaria de Salud. Farmacopea de los Estados Unidos Mexicanos. Comisión permanente de la Farmacopea de los estados unidos mexicanos, México (2008) 480-5.
(37) Arroyo J. Estudio de la penetración in-vitro a través de piel humana de pravastatina sódica formulada en parches transdérmicos de quitosán usando microagujas como promotor físico [Bachelor dissertation]. Estado de México, FESC UNAM (2014) 19-94.
(38) Villarino NF and Landoni MF. Administración Transdérmica de fármacos: una alternativa terapéutica. Analecta Veteriana (2006) 26: 28-37.